Hospital
Spring Valley Medical Center
Spring Valley Medical Center was paid $33.58M by Medicaid between Jan 2018 and Dec 2024, across 279 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoSPRING VALLEY MEDICAL CENTER
LAS VEGAS, NV 89118
LAS VEGAS, NV 89118
33aNPI1346230323assigned 10/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$33.58M
24GClaims1,573,726
24DCodes billed279
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#5 of 36
Median peer was paid$7.64M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 105,534 | $1.65M | |
| 2019 | 285,093 | $5.70M | |
| 2020 | 253,249 | $5.05M | |
| 2021 | 242,174 | $5.23M | |
| 2022 | 234,015 | $5.41M | |
| 2023 | 249,937 | $5.62M | |
| 2024incomplete | 203,724 | $4.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 61,953 | 51,095 | $7.10M |
| G0378 | Hospital observation service, per hour | 9.8% | 28,361 | 20,368 | $3.29M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.6% | 31,888 | 28,360 | $2.89M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.4% | 9,418 | 7,904 | $2.16M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.9% | 31,541 | 26,005 | $1.65M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 15,195 | 13,003 | $1.31M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.1% | 6,278 | 5,412 | $1.05M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.9% | 4,044 | 3,360 | $982K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 43,993 | 34,598 | $782K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 30,172 | 23,837 | $758K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 34,473 | 25,788 | $754K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.9% | 1,397 | 1,205 | $622K |
267 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 34,995 | $619K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 3,665 | $492K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 10,252 | $358K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 22,500 | $320K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 93,102 | $287K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 50,165 | $258K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,268 | $255K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,599 | $253K |
| 80053 | Comprehensive metabolic panel | <1% | 52,769 | $251K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,998 | $249K |
| 0450 | Emergency room services | <1% | 4,985 | $244K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,626 | $224K |
| 84484 | <1% | 48,544 | $222K | |
| 71045 | Radiologic examination, chest; single view | <1% | 31,930 | $211K |
| 96376 | <1% | 15,710 | $205K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,056 | $189K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,816 | $170K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,538 | $166K |
| 59025 | Fetal non-stress test | <1% | 4,560 | $163K |
| 72131 | <1% | 1,285 | $159K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 108,607 | $154K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,570 | $153K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,955 | $147K |
| 76830 | Ultrasound, transvaginal | <1% | 2,041 | $146K |
| 84702 | <1% | 23,316 | $144K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,319 | $140K |
| 76801 | <1% | 2,425 | $139K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 38,240 | $135K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 9,837 | $127K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,678 | $121K |
| 70486 | <1% | 932 | $110K | |
| 83880 | <1% | 9,639 | $105K | |
| 70496 | <1% | 350 | $104K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,635 | $96K |
| 93971 | <1% | 2,110 | $95K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,325 | $92K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,290 | $87K |
| 93970 | <1% | 1,022 | $80K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,195 | $78K |
| 83690 | <1% | 24,462 | $78K | |
| 70498 | <1% | 318 | $77K | |
| 97162 | <1% | 3,269 | $76K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 453 | $75K |
| 83605 | <1% | 17,488 | $72K | |
| 90715 | <1% | 1,930 | $72K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,077 | $70K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,491 | $65K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 789 | $63K |
| 97166 | <1% | 2,738 | $61K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 6,030 | $59K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,110 | $57K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 24,063 | $55K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,196 | $48K |
| 81001 | <1% | 34,932 | $47K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,992 | $45K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,465 | $45K |
| 85730 | <1% | 23,305 | $44K | |
| 73564 | <1% | 2,244 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,616 | $43K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 696 | $41K |
| 87040 | <1% | 8,724 | $40K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,373 | $39K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 927 | $38K |
| 85610 | <1% | 28,500 | $36K | |
| 73630 | <1% | 2,194 | $34K | |
| 85379 | <1% | 7,873 | $34K | |
| 73610 | <1% | 1,897 | $32K | |
| 83735 | <1% | 13,516 | $31K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,778 | $30K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,778 | $30K |
| 81025 | <1% | 11,818 | $30K | |
| 97116 | <1% | 4,669 | $29K | |
| 73130 | <1% | 1,657 | $29K | |
| 84145 | <1% | 3,051 | $27K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,712 | $26K |
| 87641 | <1% | 4,888 | $26K | |
| 73030 | <1% | 1,805 | $25K | |
| 93017 | <1% | 1,410 | $24K | |
| 74022 | <1% | 986 | $24K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,013 | $24K |
| 97161 | <1% | 1,100 | $23K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,603 | $23K |
| 11043 | <1% | 181 | $21K | |
| 72100 | <1% | 1,461 | $21K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,889 | $21K |
| 87186 | <1% | 5,992 | $20K | |
| 80076 | <1% | 5,824 | $20K | |
| 73110 | <1% | 973 | $20K | |
| 82550 | <1% | 7,416 | $19K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,338 | $18K |
| 0250 | <1% | 794 | $17K | |
| 70491 | <1% | 100 | $17K | |
| 80069 | <1% | 7,167 | $16K | |
| 96367 | <1% | 1,126 | $16K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,081 | $16K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 32,059 | $16K |
| 82962 | <1% | 22,776 | $16K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,617 | $15K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,766 | $14K |
| 93880 | <1% | 288 | $14K | |
| Z7502 | <1% | 359 | $13K | |
| 80061 | Lipid panel | <1% | 3,316 | $13K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,422 | $13K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,646 | $12K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 3,239 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,724 | $12K |
| 81003 | <1% | 11,743 | $11K | |
| 82803 | <1% | 1,749 | $11K | |
| 10060 | <1% | 148 | $11K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 308 | $10K |
| 86140 | <1% | 5,715 | $10K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 9,075 | $10K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 595 | $10K |
| 74018 | <1% | 927 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,803 | $9K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,542 | $9K |
| 12001 | <1% | 256 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,257 | $9K |
| 87077 | <1% | 2,264 | $8K | |
| 85027 | <1% | 4,818 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 34 | $8K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 316 | $8K |
| 97165 | <1% | 497 | $7K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,003 | $7K |
| 86901 | <1% | 7,557 | $7K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 77 | $7K |
| J3490 | Unclassified drugs | <1% | 570 | $6K |
| 86850 | <1% | 5,775 | $6K | |
| 87070 | <1% | 2,269 | $6K | |
| 86900 | <1% | 7,153 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 74 | $6K |
| 82140 | <1% | 1,301 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 8,341 | $5K |
| C1781 | Mesh (implantable) | <1% | 108 | $5K |
| 73502 | <1% | 318 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,942 | $5K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,967 | $5K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,683 | $4K |
| 84439 | <1% | 1,357 | $4K | |
| 76775 | <1% | 184 | $4K | |
| 73080 | <1% | 251 | $4K | |
| 87205 | <1% | 2,711 | $4K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 540 | $4K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,513 | $4K |
| 99199 | Unlisted special service, procedure or report | <1% | 79 | $4K |
| 12011 | <1% | 88 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,817 | $4K |
| J0456 | Injection, azithromycin, 500 mg | <1% | 1,346 | $3K |
| J2358 | Injection, olanzapine, long-acting, 1 mg | <1% | 356 | $3K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 139 | $3K |
| 73590 | <1% | 283 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 143 | $3K |
| 87210 | <1% | 1,543 | $3K | |
| 71101 | <1% | 149 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,028 | $3K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,158 | $3K |
| 84132 | <1% | 2,299 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,533 | $3K |
| 72128 | <1% | 30 | $2K | |
| 82728 | <1% | 713 | $2K | |
| 99070 | <1% | 268 | $2K | |
| 84100 | <1% | 1,754 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 191 | $2K |
| 36430 | <1% | 131 | $2K | |
| 72040 | <1% | 167 | $2K | |
| 95819 | <1% | 16 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 785 | $2K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,247 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,192 | $2K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 205 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 948 | $2K |
| 87631 | <1% | 912 | $2K | |
| C1769 | Guide wire | <1% | 1,545 | $2K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,335 | $2K |
| 80074 | <1% | 111 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 27 | $2K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 56 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 310 | $1K |
| 76870 | <1% | 62 | $1K | |
| 85652 | <1% | 1,527 | $1K | |
| 97163 | <1% | 83 | $1K | |
| 82010 | <1% | 415 | $1K | |
| 0270 | <1% | 269 | $1K | |
| 94664 | <1% | 282 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,632 | $1K |
| Z7610 | <1% | 122 | $1K | |
| 73090 | <1% | 86 | $1K | |
| 29125 | <1% | 52 | $1K | |
| 84112 | <1% | 80 | $1K | |
| 76376 | <1% | 63 | $1K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 420 | $1K |
| 87276 | <1% | 343 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,459 | $980.93 |
| 87275 | <1% | 342 | $976.86 | |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 123 | $942.80 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 61 | $853.73 |
| 86923 | <1% | 135 | $829.73 | |
| 87081 | <1% | 607 | $819.76 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 33 | $817.80 |
| 83615 | <1% | 454 | $762.95 | |
| 17250 | <1% | 18 | $732.48 | |
| 94644 | <1% | 35 | $719.51 | |
| 85018 | <1% | 1,289 | $718.92 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 166 | $706.26 |
| 82330 | <1% | 155 | $688.01 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 400 | $677.25 |
| 85014 | <1% | 1,221 | $670.36 | |
| G0008 | Administration of influenza virus vaccine | <1% | 82 | $668.40 |
| 99201 | <1% | 35 | $634.40 | |
| 72072 | <1% | 31 | $577.67 | |
| 97167 | <1% | 65 | $572.31 | |
| 96368 | <1% | 70 | $542.58 | |
| 86780 | <1% | 88 | $536.31 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 22 | $461.79 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 181 | $455.61 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 142 | $425.50 |
| 87486 | <1% | 36 | $406.98 | |
| 87581 | <1% | 36 | $406.98 | |
| 82805 | <1% | 44 | $404.81 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 285 | $404.47 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 26 | $295.36 |
| 82570 | <1% | 130 | $293.99 | |
| 87430 | <1% | 113 | $288.14 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 164 | $283.51 |
| 84550 | <1% | 136 | $268.98 | |
| 83550 | <1% | 169 | $268.14 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 66 | $267.92 |
| 87563 | <1% | 17 | $264.31 | |
| 87420 | <1% | 48 | $246.79 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 910 | $244.68 |
| 83540 | <1% | 159 | $194.81 | |
| 90686 | <1% | 54 | $193.81 | |
| A9270 | Non-covered item or service | <1% | 26,415 | $184.89 |
| 84295 | <1% | 179 | $177.56 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 37 | $138.97 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $132.42 |
| 97602 | <1% | 13 | $130.63 | |
| 36600 | <1% | 53 | $121.50 | |
| 64488 | <1% | 17 | $110.88 | |
| 84156 | <1% | 56 | $95.24 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 781 | $87.77 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 47 | $87.68 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 45 | $80.23 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 80 | $52.96 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 17 | $44.51 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 185 | $40.41 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 42 | $31.19 |
| 82150 | <1% | 38 | $26.96 | |
| 85046 | <1% | 34 | $22.86 | |
| 82248 | <1% | 16 | $20.52 | |
| 84300 | <1% | 14 | $13.28 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 45 | $9.16 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 146 | $8.62 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 28 | $6.70 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 257 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 250 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 244 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 16 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 336 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 411 | $0.00 |
| 0353U | 0% | 535 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 27 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 175 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 365 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 36 | $0.00 |
| C1729 | Catheter, drainage | 0% | 17 | $0.00 |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.